The biologics product portfolio includes Axograft DBM Putty, Axograft Cancellous Crushed Allograft, Axograft Crunch Allograft and Axograft Amniotic Membrane.

X-spine CEO Dr David Kirschman said: "We are excited to expand our spinal treatment portfolio with the addition of the X-spine Axograft line of biologics.

"This launch exemplifies our continuing strategy to extend the X-spine footprint beyond our fixation products, and incorporate a broader view of the treatment of spine disease into biological and interventional arenas."

The Axograft products can be used in spinal fusion, bone healing and wound treatment in spinal arthrodesis procedures.

In this year, the company also launched the Silex Sacroiliac Joint Fusion System, Axle-X Interspinous Fusion System, Irix-C Cervical Integrated Fusion System, Xpress Minimally Invasive Pedicle Screw System and the Zyfix Facet Fusion System.

The firm is also planning to launch recently USFDA-cleared Irix-A Lumbar Integrated Fusion System by the end of this year.

X-spine markets its products in the Americas, Europe, the Middle East, Africa and Australasia.